Transgenomic platform combines with NorDiag diagnostic test in fight against colorectal and pancreatic cancer
NorDiag and Transgenomic have entered into an exclusive license and supply agreement which will unite th e two companies' technologies in the fight against colorectal and pancreatic cancer.
Transgenomic has granted NorDiag exclusive European commercial rights to use its proprietary Wave system and associated consumables to perform molecular diagnostic testing for the detection of colorectal and pancreatic cancer from stool samples.
NorDiag, in return, will pay a licensing fee and has committed to certain minimum annual purchases.
NorDiag successfully employs the Wave System in its Genefec test, which can detect mutations associated with early development of gastrointestinal cancers such as colorectal cancer (CRC).
CRC is the second most common cause of cancer mortality, and early detection has been shown to significantly improve patients' long-term survival prospects.
Transgenomic's platform is integral to the automation of the Genefec test and the optimization of its sensitivity.
Commenting on the agreement, Christian Horn, CEO of NorDiag, said, "The exclusive European license to Transgenomic's proven technology, which has been adopted in medical centers and research institutions spanning more than 35 countries, will further strengthen NorDiag's position as an emerging European leader in molecular diagnostic testing".
"Following our initial success in the Scandinavian market, we are preparing to introduce Genefec to additional European markets".
"Transgenomic's Wave System is an important component in the automation and standardization of Genefec testing".
"In addition, the structured supply agreement with Transgenomic should provide a safeguard to the level of service that we provide to our customers." Collin D'Silva, CEO of Transgenomic, added, "We are pleased that NorDiag has identified our Wave System as the platform of choi ce for their novel Genefec test".
"NorDiag's proprietary sample preparation methods are an excellent complement to our high-sensitivity mutation detection technology".
"We believe this test offers significant benefit to patients, and that the success of the Wave System in this setting demonstrates its potential application in a variety of related areas."
